Tivicay Approval History
- FDA approved: Yes (First approved August 12th, 2013)
- Brand name: Tivicay
- Generic name: dolutegravir
- Company: ViiV Healthcare
- Treatment for: HIV Infection
Tivicay (dolutegravir) is an integrase inhibitor indicated for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1.
Development History and FDA Approval Process for Tivicay
|Aug 12, 2013||FDA Approves Tivicay (dolutegravir) to Treat HIV Infection|
|Dec 18, 2012||ViiV Healthcare Announces Regulatory Submissions for Dolutegravir in the EU, US and Canada|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.